Joel Neoh To Head CircleDNA As Managing Director

Genomics and precision oncology company, Prenetics Global Limited (NASDAQ: PRE) has appointed Joel Neoh to head CircleDNA as Managing Director. In addition to the role, Joel will also be taking on the role of Chief Consumer Officer of the group.

Joel’s appointment comes as Prenetics is on the move to forge ahead to reinvent the preventive healthcare landscape, with a focus on harmonising consumer health and genetics, breakthrough technology for early cancer detection, and targeted therapy for cancer treatment.

The company also aims to significantly expand into new verticals and introduce new personalised healthcare offerings to consumers within CircleDNA.

The expanded direction will further include local country partnerships to incorporate a wide spectrum of services such as blood tests, telehealth services, personalised supplements and online to offline healthcare services. The new offerings are scheduled to roll out over the next 12 months.

In all honesty, after my recent departure from Fave, I had planned an extended vacation and even organised travel plans through mid-2024. Yet, life often surprises us. Casual chats with Danny, a close friend of over ten years, took an unexpected turn. The mission of Prenetics and CircleDNA, dedicated to providing an expansive healthcare ecosystem, thoroughly intrigued me. Realising the immense potential for us to positively affect  lives, helping them to live healthier and happier, I made a conscious decision to shelve the vacation and join the cause,”shared Joel Neoh, Managing Director of CircleDNA.

Danny Yeung, CEO of Prenetics shares, “I couldn’t be more thrilled about teaming up with Joel to address some of the most pressing healthcare challenges worldwide. The healthcare landscape is undeniably complex, but I have unwavering confidence that with Joel leading CircleDNA, we are poised for significant growth while positively impacting the lives of millions across the globe. Moreover, our clinical genomics business has made remarkable strides, as evidenced by being the first Asia-based company to receive FDA clearance for a comprehensive Genomic Profiling Test. Given that this year is marked by transformation, rest assured that there are more groundbreaking developments on the horizon.”

Related articles

KWAP Set To Invest RM500 Million Through Dana Perintis Into Venture And Startup Ecosystem

Kumpulan Wang Persaraan (Diperbadankan) announced today the launch...

WAHDAH Introduces DRIVE, the Future of Fleet Management

WAHDAH Technologies Sdn. Bhd. has officially launched its newest...

Small Biz Summit 2023: Paving the Way for SMEs and Creative Entrepreneurs

Cult Creative, the organisers of Small Biz Summit 2023,...

Athena: The Mobile Game With A Voice To Make A Change

In collaboration with Sunway iLabs, Disruptr will be featuring...


Please enter your comment!
Please enter your name here